• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BARD PERIPHERAL VASCULAR, INC. VENAFLO VASCULAR GRAFT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BARD PERIPHERAL VASCULAR, INC. VENAFLO VASCULAR GRAFT Back to Search Results
Model Number VLT4046C
Device Problem Obstruction of Flow (2423)
Patient Problems Swelling (2091); Thrombus (2101)
Event Date 08/02/2020
Event Type  Injury  
Manufacturer Narrative
As the lot number for the device was provided, a manufacturing review will be performed.The sample was not returned to the manufacturer for inspection/evaluation.Therefore, the investigation of the reported event is inconclusive.Based upon the available information, the definitive root cause for this event is unknown.The instructions for use (ifu) is adequate for the reported device/patient code(s) and provides general instructions for use, as well as warnings, precautions and potential complications associated with the device.Upon receipt of new or additional information, a follow-up report will be submitted as applicable.(expiration date: 06/2023).
 
Event Description
It was reported one day post vascular graft placement, there was no murmur or tremor.Ultrasound demonstrated thrombi within the graft and the graft was removed and revealed a collapsed lumen.A new graft was placed and blood flow was restored.The current patient status was not provided.
 
Event Description
It was reported one day post vascular graft placement, there was no murmur or tremor.Reportedly an ultrasound demonstrated thrombi within the graft and the graft was removed and revealed a collapsed lumen.A new graft was placed and blood flow was restored.The current patient status was not provided.
 
Manufacturer Narrative
H10: manufacturing review: a lot history review was conducted and determined that a manufacturing review was not required.Investigation summary:the investigation is inconclusive for the reported obstruction of flow within the lumen of the graft as the device was not returned for evaluation.The definitive root cause for the reported obstruction of flow within the lumen of the graft could not be determined based up on the available information.Labeling review:the review of the ifu (instructions for use), indications, warnings, precautions, cautions, possible complications, and contraindications showed that the product labeling is adequate.H11:section a through f - the information provided by bd represents all of the known information at this time.Despite good faith efforts to obtain additional information, the complainant / reporter was unable or unwilling to provide any further patient, product, or procedural details to bd.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
VENAFLO VASCULAR GRAFT
Type of Device
VASCULAR GRAFT
Manufacturer (Section D)
BARD PERIPHERAL VASCULAR, INC.
1625 w 3rd st.
tempe AZ 85281
MDR Report Key10453738
MDR Text Key204361448
Report Number2020394-2020-05504
Device Sequence Number1
Product Code DSY
UDI-Device Identifier00801741020582
UDI-Public(01)00801741020582
Combination Product (y/n)N
PMA/PMN Number
K052282
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Type of Report Initial,Followup
Report Date 12/17/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received08/26/2020
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Model NumberVLT4046C
Device Catalogue NumberVLT4046C
Device Lot NumberVTCT0250
Was Device Available for Evaluation? No
Date Manufacturer Received12/08/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention;
Patient Age53 YR
-
-